Source · Select Committees · Health and Social Care Committee
Recommendation 15
15
Paragraph: 95
For patients with limited treatment options the approval of a new drug or therapy can...
Conclusion
For patients with limited treatment options the approval of a new drug or therapy can make a significant difference even when the survival benefit is only months. Despite the effectiveness of the Medicines and Healthcare products Regulatory Agency’s regulatory process, and despite some progress by NICE in approving medicines more efficiently for use in the NHS, the whole process is still too slow.
Paragraph Reference:
95
Government Response
A response document is linked to this report, dated 13 June 2022. Response attribution to this conclusion has not been verified. Read the response document ↗